Determinants of Changes in Arterial Load Following Exercise
NCT ID: NCT05820243
Last Updated: 2023-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
25 participants
INTERVENTIONAL
2023-05-12
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To accomplish these aims, blood flow leaving the left ventricle and femoral blood flow will be measured via Doppler ultrasound. Applanation tonometry will be used to record pulse waves at the carotid, radial, femoral, and dorsalis pedis arteries. These pulse waves will be used to estimate central blood pressure and to determine pulse wave velocity of different arterial segments. Measurements will be made at baseline and for 120 minutes after a bout of moderate intensity aerobic exercise.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antihistamine
The oral antihistamine condition will consist of fexofenadine (540mg) and famotidine (40mg). Commercially available pills (3 x 180mg fexofenadine and 2 x 20mg famotidine) will be placed within opaque capsules and administered to the participants upon arrival to the laboratory.
Moderate Intensity Aerobic Exercise
Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
Placebo
The placebo condition will consist of dextrose in an identical number of opaque capsules as the antihistamine treatment. Total dextrose will be \<5g. The capsules will be administered to the participants upon arrival to the laboratory.
Moderate Intensity Aerobic Exercise
Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moderate Intensity Aerobic Exercise
Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* sedentary or recreationally active
Exclusion Criteria
* stage 2 hypertension (BP: ≥140 systolic or ≥90 diastolic)
* metabolic syndrome
* renal disease
* chronic respiratory disease
* currently prescribed any cardiovascular medication
* current use of erythromycin and/ ketoconazole
* current pregnancy or breastfeeding -hormone replacement therapy-
* tobacco use
* musculoskeletal injury/disorder that would inhibit cycling exercise
* body mass index (BMI) \<18.5 or \>35kg/m\^2
* reduced kidney function (estimated glomerular filtration rate\< 90ml/min/1.73 m\^2)
* daily use of fexofenadine and/or famotidine
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Delaware
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Edwards
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Kinesiology and Applied Physiology, University of Delaware
Newark, Delaware, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1783804
Identifier Type: -
Identifier Source: org_study_id